Unión Europea - esloveno - EMA (European Medicines Agency)

eisai gmbh - beksaroten - limfom, t-celica, kožni - antineoplastična sredstva - targretin kapsule so indiciran za zdravljenje kože manifestacije poznejši fazi kožna t-celični limfom (ctcl) bolniki neodzivna na vsaj eno sistemsko zdravljenje.

Unión Europea - esloveno - EMA (European Medicines Agency)

sandoz gmbh - infliksimab - arthritis, psoriatic; psoriasis; crohn disease; arthritis, rheumatoid; colitis, ulcerative; spondylitis, ankylosing - imunosupresivi - zdravljenje revmatoidni artritis, crohnova bolezen, ulcerozni kolitis, ankilozirajoči spondilitis, psoriatični artritis in luskavica.

Unión Europea - esloveno - EMA (European Medicines Agency)

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastična sredstva - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. bolniki, ki imajo nizko ali zelo nizko tveganje za ponovitev, ne bi smel imeti adjuvant treatment. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. razen v novo diagnozo kronične faze cml, ni kontroliranih preskušanjih, dokazujejo kliničnih koristi ali poveča preživetje pri teh bolezni.

Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

novartis pharma gmbh - letrozol - filmsko obložena tableta - letrozol 2,5 mg / 1 tableta - letrozol

Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

novartis pharma gmbh - mikofenolna kislina - gastrorezistentna tableta - mikofenolna kislina 180 mg / 1 tableta - mikofenolna kislina

Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

novartis pharma gmbh - mikofenolna kislina - gastrorezistentna tableta - mikofenolna kislina 360 mg / 1 tableta - mikofenolna kislina

Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

novartis pharma gmbh - terbinafin - tableta - terbinafin 250 mg / 1 tableta - terbinafin

Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mundipharma gmbh - oksikodon - tableta s podaljšanim sproščanjem - oksikodon 9 mg / 1 tableta - oksikodon

Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mundipharma gmbh - oksikodon - tableta s podaljšanim sproščanjem - oksikodon 9 mg / 1 tableta - oksikodon

Eslovenia - esloveno - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mundipharma gmbh - oksikodon - tableta s podaljšanim sproščanjem - oksikodon 36 mg / 1 tableta - oksikodon